| Detected | Trial | Change |
|---|---|---|
| 2026-08-02 | NCT04535713 GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma |
overall status: Recruiting → Unknown |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT03886311 | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma | Sarcoma | Recruiting |
| NCT04535271 | Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma | Leiomyosarcoma | Recruiting |
| NCT07671534 | Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors | Solid Tumor Cancer | Recruiting |
| NCT03778996 | SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma | Sarcoma, Ewing | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT03138161 | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue… | Advanced Soft Tissue Sarcoma | Recruiting |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | Solid Tumor, Adult | Active, Not Recruiting |